MA45937A - Inhibiteurs d'amino pyrimidine ssao - Google Patents

Inhibiteurs d'amino pyrimidine ssao

Info

Publication number: MA45937A
Authority: MA; Morocco
Prior art keywords: amino pyrimidine; ssao inhibitors; ssao; inhibitors; pyrimidine
Prior art date: 2016-08-12

Application number

MA045937A

Other languages

English (en)

Inventor

David Andrew Coates

Luo Heng Qin

Yi Wei

Jingye Zhou

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-12

Filing date

2017-08-04

Publication date

2019-06-19

2017-08-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2019-06-19 Publication of MA45937A publication Critical patent/MA45937A/fr

Links

102100027159 Membrane primary amine oxidase Human genes 0.000 title 1
101710132836 Membrane primary amine oxidase Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA045937A 2016-08-12 2017-08-04 Inhibiteurs d'amino pyrimidine ssao MA45937A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2016/094833 WO2018027892A1 (fr)	2016-08-12	2016-08-12	Inhibiteurs de ssao à base d'amino pyrimidine

Publications (1)

Publication Number	Publication Date
MA45937A true MA45937A (fr)	2019-06-19

Family

ID=61161335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA045937A MA45937A (fr)	2016-08-12	2017-08-04	Inhibiteurs d'amino pyrimidine ssao

Country Status (22)

Country	Link
US (3)	US10287270B2 (fr)
EP (3)	EP3497086B1 (fr)
JP (2)	JP7035013B2 (fr)
KR (3)	KR20240035917A (fr)
CN (2)	CN114380801B (fr)
AU (2)	AU2017309199B2 (fr)
CA (1)	CA3033687A1 (fr)
CR (1)	CR20190124A (fr)
DK (2)	DK3984996T3 (fr)
ES (2)	ES2992165T3 (fr)
HU (1)	HUE058142T2 (fr)
IL (1)	IL264745B (fr)
MA (1)	MA45937A (fr)
MX (1)	MX389672B (fr)
MY (1)	MY196576A (fr)
NZ (1)	NZ750290A (fr)
PH (1)	PH12019500296A1 (fr)
PL (2)	PL3497086T3 (fr)
PT (1)	PT3497086T (fr)
SG (1)	SG11201900844UA (fr)
WO (2)	WO2018027892A1 (fr)
ZA (2)	ZA201901097B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018027892A1 (fr)	2016-08-12	2018-02-15	Eli Lilly And Company	Inhibiteurs de ssao à base d'amino pyrimidine
WO2018148856A1 (fr)	2017-02-14	2018-08-23	Eli Lilly And Company	Composés de diazaspirodécanyl-pyrimidine utiles en tant qu'inhibiteurs de ssao
CN109810041B (zh)	2017-11-21	2023-08-15	药捷安康(南京)科技股份有限公司	卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20190110740A (ko)	2018-03-21	2019-10-01	주식회사유한양행	신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko)	2018-03-21	2019-10-01	주식회사유한양행	신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN112996795B (zh)	2018-09-18	2024-11-12	尼坎治疗公司	作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
CN110938059A (zh) *	2018-09-25	2020-03-31	上海轶诺药业有限公司	胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (fr) *	2018-09-27	2020-04-02	南京明德新药研发有限公司	Dérivés à base de quinoléine utilisés comme inhibiteurs de vap-1
CN112955215B (zh) *	2018-10-29	2024-05-17	勃林格殷格翰国际有限公司	吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955214B (zh) *	2018-10-29	2024-05-07	勃林格殷格翰国际有限公司	吡啶基磺酰胺衍生物、药物组合物及其用途
CN121081472A (zh)	2018-12-13	2025-12-09	拓臻股份有限公司	一种THRβ受体激动剂化合物及其制备方法和用途
TWI835945B (zh) *	2018-12-14	2024-03-21	南韓商柳韓洋行股份有限公司	3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh)	2018-12-14	2020-11-01	南韓商柳韓洋行股份有限公司	三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
SG11202107498VA (en) *	2019-01-11	2021-08-30	Nanjing Transthera Biosciences Co Ltd	Haloallylamine compounds and application thereof
EP4017875A4 (fr)	2019-08-23	2023-05-03	Terns Pharmaceuticals, Inc.	Composés agonistes du récepteur bêta de l'hormone thyroïdienne
AU2020346057A1 (en)	2019-09-12	2022-04-21	Terns Pharmaceuticals, Inc.	Thyroid hormone receptor beta agonist compounds
AU2020377093B2 (en)	2019-10-29	2026-02-26	Eccogene Inc.	SSAO inhibitors and use thereof
CN113149957A (zh) *	2020-01-23	2021-07-23	轶诺(浙江)药业有限公司	胺基脲敏感性胺氧化酶抑制剂制备及其应用
PE20230997A1 (es) *	2020-03-25	2023-06-26	Terns Inc	Tratamiento de trastornos respiratorios
CA3183414A1 (fr) *	2020-05-13	2021-11-18	Terns Pharmaceuticals, Inc.	Polytherapies contre des troubles hepatiques
EP4204405A4 (fr) *	2020-08-25	2024-05-29	Eli Lilly and Company	Polymorphes d'un inhibiteur de ssao
CN114621243B (zh) *	2020-12-14	2024-03-01	上海拓界生物医药科技有限公司	一种磺酰胺类衍生物及其用途
KR20220145981A (ko) *	2021-04-22	2022-11-01	주식회사유한양행	트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
EP4429665A1 (fr) *	2021-11-11	2024-09-18	Terns Pharmaceuticals, Inc.	Combinaison d'un inhibiteur de ssao et d'un agoniste de thr-bêta pour une utilisation dans le traitement de troubles hépatiques
CA3238102A1 (fr) *	2021-11-11	2023-05-19	Terns Pharmaceuticals, Inc.	Traitement de troubles hepatiques avec un inhibiteur de ssao

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2004166A2 (fr) *	2006-03-31	2008-12-24	La Jolla Pharmaceutical Company	Inhibiteurs d'adhérence médiée par l'amine oxydase sensible aux semi-carbazides (ssao) et la vap-1 utilisés dans le traitement et la prévention de maladies
WO2008123469A1 (fr)	2007-03-30	2008-10-16	Japan Tobacco Inc.	Composé amide à six chaînons et son utilisation
AU2008280784A1 (en) *	2007-07-20	2009-01-29	Merck Frosst Canada Ltd	Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2011504485A (ja)	2007-11-21	2011-02-10	ファーマクシスリミテッド	Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
JP2011136942A (ja) *	2009-12-28	2011-07-14	Kowa Co	新規な置換ピリミジン誘導体およびこれを含有する医薬
MY177070A (en)	2011-03-15	2020-09-04	Astellas Pharma Inc	Guanidine compound
PT2844637T (pt)	2012-05-02	2018-04-17	Boehringer Ingelheim Int	Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações
US9714231B2 (en) *	2012-11-16	2017-07-25	Bristol-Myers Squibb Company	Pyrrolidine GPR40 modulators
US8962641B2 (en) *	2013-04-17	2015-02-24	Boehringer Ingelheim International Gmbh	Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
EP2997024B1 (fr) *	2013-05-17	2018-03-28	Boehringer Ingelheim International GmbH	Dérivés pyrrolidines, compositions pharmaceutiques les comprenant et leurs utilisations
GB201416444D0 (en)	2014-09-17	2014-10-29	Proximagen Ltd	New compounds
WO2018027892A1 (fr)	2016-08-12	2018-02-15	Eli Lilly And Company	Inhibiteurs de ssao à base d'amino pyrimidine
WO2018148856A1 (fr)	2017-02-14	2018-08-23	Eli Lilly And Company	Composés de diazaspirodécanyl-pyrimidine utiles en tant qu'inhibiteurs de ssao

2016
- 2016-08-12 WO PCT/CN2016/094833 patent/WO2018027892A1/fr not_active Ceased
2017
- 2017-08-04 CA CA3033687A patent/CA3033687A1/fr active Pending
- 2017-08-04 HU HUE17838647A patent/HUE058142T2/hu unknown
- 2017-08-04 EP EP17838647.0A patent/EP3497086B1/fr active Active
- 2017-08-04 CR CR20190124A patent/CR20190124A/es unknown
- 2017-08-04 EP EP21206067.7A patent/EP3984996B1/fr active Active
- 2017-08-04 AU AU2017309199A patent/AU2017309199B2/en active Active
- 2017-08-04 PL PL17838647T patent/PL3497086T3/pl unknown
- 2017-08-04 KR KR1020247007555A patent/KR20240035917A/ko not_active Ceased
- 2017-08-04 MY MYPI2019000694A patent/MY196576A/en unknown
- 2017-08-04 PL PL21206067.7T patent/PL3984996T3/pl unknown
- 2017-08-04 MX MX2019001581A patent/MX389672B/es unknown
- 2017-08-04 WO PCT/CN2017/095999 patent/WO2018028517A1/fr not_active Ceased
- 2017-08-04 CN CN202111597465.6A patent/CN114380801B/zh active Active
- 2017-08-04 SG SG11201900844UA patent/SG11201900844UA/en unknown
- 2017-08-04 DK DK21206067.7T patent/DK3984996T3/da active
- 2017-08-04 JP JP2019507302A patent/JP7035013B2/ja active Active
- 2017-08-04 ES ES21206067T patent/ES2992165T3/es active Active
- 2017-08-04 MA MA045937A patent/MA45937A/fr unknown
- 2017-08-04 PT PT178386470T patent/PT3497086T/pt unknown
- 2017-08-04 EP EP24204999.7A patent/EP4501323A3/fr not_active Withdrawn
- 2017-08-04 KR KR1020227045793A patent/KR102646063B1/ko active Active
- 2017-08-04 KR KR1020197005543A patent/KR102483876B1/ko active Active
- 2017-08-04 ES ES17838647T patent/ES2908805T3/es active Active
- 2017-08-04 CN CN201780006868.4A patent/CN108884056B/zh active Active
- 2017-08-04 DK DK17838647.0T patent/DK3497086T3/da active
- 2017-08-04 NZ NZ750290A patent/NZ750290A/en unknown
2018
- 2018-06-19 US US16/011,855 patent/US10287270B2/en active Active
2019
- 2019-02-10 IL IL264745A patent/IL264745B/en unknown
- 2019-02-12 PH PH12019500296A patent/PH12019500296A1/en unknown
- 2019-02-20 ZA ZA2019/01097A patent/ZA201901097B/en unknown
- 2019-03-18 US US16/356,882 patent/US10464928B2/en active Active
- 2019-09-26 US US16/584,622 patent/US10793552B2/en active Active
2021
- 2021-09-14 JP JP2021149451A patent/JP7372957B2/ja active Active
2022
- 2022-02-18 ZA ZA2022/02097A patent/ZA202202097B/en unknown
- 2022-05-06 AU AU2022203071A patent/AU2022203071B2/en active Active

Also Published As

Publication number	Publication date
ES2908805T3 (es)	2022-05-04
ZA202202097B (en)	2023-11-29
PL3984996T3 (pl)	2025-03-10
US10464928B2 (en)	2019-11-05
JP2019527717A (ja)	2019-10-03
MY196576A (en)	2023-04-19
IL264745B (en)	2021-08-31
JP2022003049A (ja)	2022-01-11
CN114380801A (zh)	2022-04-22
CN108884056A (zh)	2018-11-23
WO2018027892A1 (fr)	2018-02-15
AU2022203071B2 (en)	2024-06-20
AU2017309199B2 (en)	2022-05-12
AU2017309199A1 (en)	2019-02-21
KR102646063B1 (ko)	2024-03-12
PL3497086T3 (pl)	2022-05-02
JP7035013B2 (ja)	2022-03-14
KR20190038580A (ko)	2019-04-08
BR112019002275A2 (pt)	2019-06-18
EP3497086A1 (fr)	2019-06-19
AU2022203071A1 (en)	2022-05-26
EP3497086A4 (fr)	2020-03-25
DK3984996T3 (da)	2024-10-21
US10287270B2 (en)	2019-05-14
MX2019001581A (es)	2019-06-20
EP4501323A3 (fr)	2025-03-19
ZA201901097B (en)	2022-08-31
KR102483876B1 (ko)	2023-01-03
NZ750290A (en)	2022-09-30
DK3497086T3 (da)	2022-03-14
EP4501323A2 (fr)	2025-02-05
ES2992165T3 (es)	2024-12-09
CN108884056B (zh)	2022-01-07
WO2018028517A1 (fr)	2018-02-15
US20180297987A1 (en)	2018-10-18
EP3984996B1 (fr)	2024-10-09
JP7372957B2 (ja)	2023-11-01
SG11201900844UA (en)	2019-02-27
CR20190124A (es)	2019-05-13
EP3497086B1 (fr)	2021-12-15
CA3033687A1 (fr)	2018-02-15
US20200262817A1 (en)	2020-08-20
HUE058142T2 (hu)	2022-07-28
US10793552B2 (en)	2020-10-06
CN114380801B (zh)	2025-07-29
KR20230008889A (ko)	2023-01-16
PT3497086T (pt)	2022-03-14
US20190276436A1 (en)	2019-09-12
EP3984996A1 (fr)	2022-04-20
MX389672B (es)	2025-03-20
PH12019500296A1 (en)	2019-05-15
KR20240035917A (ko)	2024-03-18

Publication	Publication Date	Title
MA45937A (fr)	2019-06-19	Inhibiteurs d'amino pyrimidine ssao
IL282090A (en)	2021-05-31	Tyk2 inhibitors and uses thereof
DK3497103T3 (da)	2021-06-14	Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3526222A4 (fr)	2020-08-26	Inhibiteurs de tyk2 et leurs utilisations
EP3626699A4 (fr)	2020-04-22	Inhibiteur de ssao
EP3528816A4 (fr)	2020-04-08	Inhibiteurs de tyk2 et leurs utilisations
IL268625A (en)	2019-10-31	Amino pyrimidine compounds used as SSAO inhibitors
EP3430731A4 (fr)	2019-10-09	Architecture d'iugw
EP3383967A4 (fr)	2019-07-10	Inhibiteurs d'entartrage solides à libération contrôlée
MA52004A (fr)	2021-01-20	Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA49006A (fr)	2020-02-05	Inhibiteurs d'ip6k
MA50906A (fr)	2020-09-23	Inhibiteurs d'immunoprotéasome
EP3555092A4 (fr)	2020-05-13	Inhibiteurs de protéine kinase
EP3431808A4 (fr)	2019-04-03	Butée d'arrêt
MA53648A (fr)	2021-07-28	Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
DK3621948T3 (da)	2021-06-14	Amino(meth)acrylater
ZA201808238B (en)	2022-10-26	Certain protein kinase inhibitors
EP3480212C0 (fr)	2023-09-27	Peptide il13ralpha2 et ses utilisations
EP3368401A4 (fr)	2019-10-09	Adaptateur d'ancrage
DK3706710T3 (da)	2024-07-08	Formuleringer med forlænget frigivelse til intraartikulære anvendelser
DK3402573T3 (da)	2023-05-30	Aminosyreholdig sammensætning
IT201700035964A1 (it)	2018-10-01	“divisorio per boiserie”
HK40010000A (en)	2020-07-03	Amino pyrimidine ssao inhibitors
UA34203S (uk)	2017-03-27	Підвіска «зігфрід»
UA35584S (uk)	2017-10-25	Ювелірний виріб «оберіг»